Altimmune, Inc. Files 8-K Report
Ticker: ALT · Form: 8-K · Filed: Jun 26, 2025 · CIK: 1326190
| Field | Detail |
|---|---|
| Company | Altimmune, Inc. (ALT) |
| Form Type | 8-K |
| Filed Date | Jun 26, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-statements, regulation-fd
TL;DR
Altimmune filed an 8-K on June 26, 2025, mostly for financial statements and exhibits.
AI Summary
On June 26, 2025, Altimmune, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates Altimmune, Inc. is providing updated information to the SEC, which could include material events or financial updates relevant to investors.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, with no immediate indication of significant new risks or material adverse events.
Key Players & Entities
- Altimmune, Inc. (company) — Registrant
- June 26, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Gaithersburg, Maryland (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing by Altimmune, Inc.?
The primary purpose of this 8-K filing, dated June 26, 2025, is to report financial statements and exhibits, along with other events and a Regulation FD disclosure.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on June 26, 2025.
Where are Altimmune, Inc.'s principal executive offices located?
Altimmune, Inc.'s principal executive offices are located at 910 Clopper Road, Suite 201S, Gaithersburg, Maryland.
What is Altimmune, Inc.'s state of incorporation?
Altimmune, Inc. is incorporated in Delaware.
What is the SIC code for Altimmune, Inc.?
The Standard Industrial Classification (SIC) code for Altimmune, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 26, 2025 regarding Altimmune, Inc. (ALT).